Livagen dosing & administration
Tetrapeptide bioregulator (Lys-Glu-Asp-Ala) that directly penetrates cell nuclei and binds double-stranded DNA to induce chromatin decondensation in senescent lymphocytes, activate ribosomal genes, inhibit enkephalin-degrading enzymes with an IC50 of 20 μM, and restore protein synthesis capacity in aging cells through selective epigenetic remodeling
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Intramuscular: An injection into a muscle, usually the thigh, shoulder, or buttock.
Bioavailability High — well absorbed into the bloodstream from the muscle.
5-10 mg
Frequency
Once daily
Duration
10-day course (50-100 mg total)
Reflects the Khavinson-laboratory bioregulator course used in practice: a total of 50-100 mg of the KEDA tetrapeptide delivered over 10 days. Livagen has no standardized human clinical dosing; evidence is largely preclinical [6].
Timing
Best time to take
Administer Livagen at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Livagen injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Livagen should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Livagen in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Livagen should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Intramuscular injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Livagen. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Injection site reaction, Mild fatigue, Mild headache, Digestive enzyme changes
Less common: Transient flu-like symptoms
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Livagen
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Livagen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Opioid medications (Livagen inhibits enkephalinase with IC50 of 20 μM, potentially prolonging endogenous opioid activity) — Use with caution—discuss with your healthcare provider.
- Immunosuppressive drugs without medical supervision — chromatin reactivation may enhance immune gene expression — Use with caution—discuss with your healthcare provider.
- Other potent peptidase inhibitors — potential for additive effects on enzyme inhibition — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Khavinson VKh, Lezhava TA, Monaselidze JG · 2002
Livagen peptide reactivates silenced genes in aging immune cells by loosening chromatin condensation, helping restore cellular function and immune vigor in elderly people.
Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VK · 2003
Research (2003) on livagen contributes important scientific knowledge about its biological and pharmacological properties.
Khavinson VKh, Lezhava TA, Malinin VV, Monaselidze JR · 2004
Research (2004) on livagen contributes important scientific knowledge about its biological and pharmacological properties.
Khavinson VK, Popovich IG, Linkova NS · 2021
Research (2021) on livagen contributes important scientific knowledge about its biological and pharmacological properties.
Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK · 2020
Liver polypeptide complex and KEDA tetrapeptide (livagen) restore immune and antioxidant defenses while recovering liver function during hepatitis, especially effective in aging.
PeptideInsight · 2024
Khavinson-laboratory course protocol delivers a total of 50-100 mg of the KEDA tetrapeptide over 10 days (intramuscular or subcutaneous); no standardized human clinical dosing, evidence largely preclinical.
Head to head
Livagen compared
Want the full picture?
The complete Livagen research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.